ICAD

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

Retrieved on: 
Tuesday, April 9, 2024
Health, Culture, EQUIP, Algorithm, Radiology, Partnership, Risk, ICAD, Physician, Patient, ACR, Accreditation, Mammography, Deep learning, GPT, DBT, Breast cancer, Safety, Machine learning, Breast, Medical imaging

Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluation

Key Points: 
  • Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluation
    NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc .
  • (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced a strategic partnership with Densitas, Inc ., a global leader in operational AI solutions for breast cancer screening.
  • The partnership enables breast imaging centers and radiologists to provide end-to-end breast health care that ensures every aspect of a woman’s breast health journey is addressed, starting from the first step of quality screening mammograms and extending through breast cancer detection, breast density assessment, and a comprehensive evaluation of breast cancer risk.
  • IntelliMammo® densityAI™ breast density has been clinically validated to have a strong association with breast cancer risk, providing a practical automated method for risk stratification.vi

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

Retrieved on: 
Monday, April 8, 2024
Prevalence, Cardiovascular disease, Sudden death, Radiology, Blood, Risk, Physician, ICAD, Patient, Ageing, Stroke, Research, Breast, Angiography, Death, Woman, American College, Breast cancer, Literature, Prognosis, Moyamoya disease, ACC, Medical imaging

The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.

Key Points: 
  • The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.
  • “The ProFound BAC AI algorithm may provide a critical surrogate biomarker for women at risk of heart disease or stroke,” said Dana Brown, president and CEO of iCAD.
  • The study also suggests the ProFound Heart Health AI algorithm can standardize BAC detection, potentially improving efficiency and reducing variability among observers.
  • Early cardiovascular disease detection is key, as among asymptomatic women, the first manifestation of underlying coronary heart disease is often acute myocardial infarction (MI) or sudden death.

iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)

Retrieved on: 
Wednesday, April 3, 2024
Health equity, Partnership, ICAD, Education, Patient, Global health, Mammography, Cancer, SBI, Breast cancer, Medical imaging

(NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with RAD-AID International .

Key Points: 
  • (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with RAD-AID International .
  • RAD-AID, a non-profit charitable organization dedicated to improving radiology healthcare in medically underserved regions, is collaborating with iCAD to introduce mammography AI-based decision support in LMICs, starting with an implementation in Guyana using iCAD’s ProFound Detection.
  • iCAD and RAD-AID aim to begin in Guyana where implementation of iCAD’s ProFound AI Detection Solution, coupled with RAD-AID’s educational and capacity-building initiatives, aims to increase, and improve breast cancer detection for patients in need.
  • “Our deployment of ProFound AI Detection in Guyana represents a significant step forward in the fight against breast cancer in low-resource settings.

iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale

Retrieved on: 
Tuesday, April 2, 2024
Cloud, Google Cloud, 2D, Software as a service, Partnership, ICAD, Patient, Software, 3D, Radiology, Cancer, AI, Mammography, Workflow, Graphics processing unit, PACS, System, Privacy, Triangle, Medical imaging

NASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud.

Key Points: 
  • NASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud.
  • The innovative Software-as-a-Service (SaaS) platform provides medical providers with a cost-effective, secure, and scalable means to access and deploy the latest ProFound Breast Health Suite of AI solutions.
  • “With the commercial launch of ProFound Cloud, iCAD is enabling interoperability and access to Breast AI Solutions at enterprise scale, revolutionizing global access to cutting-edge AI solutions in breast health,” said Dana Brown, president, and CEO of iCAD.
  • ProFound Cloud also manages ProFound Risk and Density assessment results, radiology and pathology reports and detection results, while ensuring seamless access to critical diagnostic information.

iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists

Retrieved on: 
Tuesday, March 19, 2024
2D, Radiology, ICAD, 3D, Mammography, Cancer, Medical imaging

“We're excited to introduce advanced workstation features for our flagship solution, ProFound Detection, aimed at further improving and facilitating radiologists' interpretation of mammograms within their workstation,” said Dana Brown, President and CEO of iCAD.

Key Points: 
  • “We're excited to introduce advanced workstation features for our flagship solution, ProFound Detection, aimed at further improving and facilitating radiologists' interpretation of mammograms within their workstation,” said Dana Brown, President and CEO of iCAD.
  • This refinement ensures that radiologists can interpret the most critical information thereby streamlining the diagnostic process for more efficient decision-making.
  • “From the inception of iCAD’s 2D Detection in 2002, to the launch of 3D Detection V1.0 in 2016, followed by 3D V2.0 Detection in 2018, and V3.0 Detection in 2021, each version has pushed the boundaries of cancer detection solutions.
  • Now, in 2024, the release of the V3 Detection Service Pack marks another milestone, representing a commitment to ongoing enhancement and ensuring that ProFound Detection remains at the forefront of early cancer detection solutions.”

New Institute for Career Advising & Development Focuses on Moving Careers Forward

Retrieved on: 
Tuesday, March 12, 2024
ICAD, IACA, Kuder, International Association, Organization, Certification, Research, Career development, Catalog

ADEL, Iowa, March 12, 2024 /PRNewswire/ -- Kuder, Inc. (Kuder) is excited to announce the launch of a new division, the Institute for Career Advising & Development (ICAD) .

Key Points: 
  • ADEL, Iowa, March 12, 2024 /PRNewswire/ -- Kuder, Inc. (Kuder) is excited to announce the launch of a new division, the Institute for Career Advising & Development (ICAD) .
  • As career advising & development continues to evolve, it is important for professionals to advance in their practice.
  • ICAD offers a range of professional development courses that cover career development theories, research, and practice.
  • "As the field of career advising and development continues to evolve, it is important for professionals to advance in their practice," said Dr. Kim Oppelt, Kuder's Vice President of Career Development and chief contributor for ICAD.

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

Retrieved on: 
Wednesday, February 28, 2024
Scorecard, Certificate, ICAD, Medium, University, ECR, Malignancy, RPS, Diagnosis, Software, Workload, Radiology, Proxy, Neoplasm, 3D, Breast cancer, Woman, Mammography, Artificial intelligence, Research, 2D, AI, Intelligence, ICS, Death, Cancer, Medical imaging

“The data presented at ECR demonstrate the real-world ability to improve efficiency and accuracy in mammography breast screening—from reducing workloads without compromising accuracy to potentially reducing interval cancer rates and expediting diagnosis for true positive cases.

Key Points: 
  • “The data presented at ECR demonstrate the real-world ability to improve efficiency and accuracy in mammography breast screening—from reducing workloads without compromising accuracy to potentially reducing interval cancer rates and expediting diagnosis for true positive cases.
  • These findings underscore ProFound AI’s transformative power to improve breast healthcare,” said Dana Brown, president and CEO of iCAD.
  • Sunday, March 3, 9:30 – 11:00 am, RPS2305 – Retrospective Evaluation of Interval Breast Cancer: Can the Number of Interval Carcinomas be Reduced Utilizing AI Diagnostic Software?
  • Lastly, iCAD will highlight expanded cloud platform and subscription licensing plans marking a significant advancement in deployment flexibility.

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

Retrieved on: 
Tuesday, February 27, 2024
MSK, University, Research, DKFZ, Quality of life, Sidney Kimmel, Radiology, National academy, ICAD, Faculty, Molecular Pharmacology, Translation, Trustee, Johns Hopkins University, NAM, Biomedical sciences, Book, Medical device

Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field.

Key Points: 
  • Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field.
  • Dr. Hricak is a member of the National Academy of Medicine and received the David Rall Medal, the NAM award for distinguished leadership.
  • The hallmark of her academic career has been developing, translating, and disseminating new diagnostic imaging techniques, primarily for genitourinary cancers.
  • “We are thrilled to welcome Dr. Hricak to the iCAD Board of Directors,” said Dana Brown, President, CEO, and Chairman of the Board.

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Retrieved on: 
Tuesday, February 27, 2024
ICAD

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year 2023 financials after the market close, and host a conference call at 4:30 PM Eastern Time on Tuesday, March 12, 2024.

Key Points: 
  • NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year 2023 financials after the market close, and host a conference call at 4:30 PM Eastern Time on Tuesday, March 12, 2024.
  • Earnings call details are as follows:

iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on: 
Tuesday, February 6, 2024
Digital health, Conference, ICAD

NASHUA, N.H., Feb. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 12-14, 2024, in Snowbird, UT.

Key Points: 
  • NASHUA, N.H., Feb. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 12-14, 2024, in Snowbird, UT.
  • Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD, Inc., will participate in one-on-one meetings with investors at the event.
  • Please contact your BTIG representative for further information or to request a meeting.